トキソプラズマ症治療薬の世界市場レポート 2025年

トキソプラズマ症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で44億4,000万米ドルに成長します。予測期間の成長は、研究開発投資、トキソプラズマ症に対する新たな治療法、ヘルスケア支出の増加、感染症対策への世界の取り組み、個別化医療アプローチの採用などに起因すると考えられます。予測期間における主な動向には、併用薬物療法の開発、治療戦略における精密医療の統合、早期診断と介入の重視、カスタマイズされた治療レジメン、ドラッグデリバリー方法の進歩などが含まれます。

トキソプラズマ症感染の有病率の増加は、今後のトキソプラズマ症治療薬市場の成長を促進すると予想されます。トキソプラズマ症は、原虫寄生体であるトキソプラズマ・ゴンディによってヒトと動物の両方に引き起こされる感染症と病気を指します。トキソプラズマ症感染の増加は、ピリメタミン、スピラマイシン、ロイコボリンなど、特定のタイプのトキソプラズマ症患者の治療に使用される医薬品の需要を高め、それによってこれらの治療薬の市場を押し上げます。例えば、2024年2月、英国の政府機関であるUK Health Security Agencyが発表したデータによると、2023年第2四半期に54件のトキソプラズマ症確定症例が報告され、2022年同時期の37件から増加しています。その結果、トキソプラズマ症感染の有病率の上昇がトキソプラズマ症治療薬市場の成長を促進しています。

老年人口の増加は、今後のトキソプラズマ症治療薬市場の成長を促進すると予想されます。老年医学は、正確に定義することが困難な人口層である高齢者の医療に焦点を当てています。高齢者のトキソプラズマ症治療には、包括的なアプローチが必要です。この感染症に直面している高齢者に最適な治療を保証するためには、個別化された治療計画によって有効性と安全性のバランスをとり、新薬や治療法の研究に投資し、予防を重視することが不可欠です。例えば、2023年1月、国連事務局の米国機関である国連経済社会局（UN DESA）は、世界の65歳以上の高齢者数が2倍以上に増加し、2021年の7億6,100万人から2050年には16億人になると予測しています。このように、老人人口の増加がトキソプラズマ症治療薬市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界トキソプラズマ症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のトキソプラズマ症治療薬市場：成長率分析
• 世界のトキソプラズマ症治療薬市場の実績：規模と成長, 2019-2024
• 世界のトキソプラズマ症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界トキソプラズマ症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のトキソプラズマ症治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ピリメタミン
• スピラマイシン
• ロイコボリン
• スルファジアジン
• 葉酸
• その他の薬物クラス
• 世界のトキソプラズマ症治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性トキソプラズマ感染症
• 急性トキソプラズマ感染症
• 世界のトキソプラズマ症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• オーラル
• 世界のトキソプラズマ症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のトキソプラズマ症治療薬市場ピリメタミンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド名のバリエーション
• 併用療法
• 世界のトキソプラズマ症治療薬市場、スピラマイシンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド名のバリエーション
• 処方
• 世界のトキソプラズマ症治療薬市場、ロイコボリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 剤形
• 世界のトキソプラズマ症治療薬市場、スルファジアジンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド名のバリエーション
• 併用療法
• 世界のトキソプラズマ症治療薬市場、葉酸の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サプリメント処方
• 他の薬剤との併用製品
• 世界のトキソプラズマ症治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アトバコン
• クリンダマイシン
• トリメトプリム-スルファメトキサゾール（TMP-SMX）
• 実験的または新興の治療法

第7章 地域別・国別分析

• 世界のトキソプラズマ症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のトキソプラズマ症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• トキソプラズマ症治療薬市場：競合情勢
• トキソプラズマ症治療薬市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Otsuka Pharmaceutical Co. Ltd.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• AstraZeneca plc
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• トキソプラズマ症治療薬市場2029：新たな機会を提供する国
• トキソプラズマ症治療薬市場2029：新たな機会を提供するセグメント
• トキソプラズマ症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Toxoplasmosis treatment drugs are pharmaceutical products or medications designed to manage infectious diseases caused by Toxoplasma gondii. These drugs are utilized to treat parasitic infections resulting from exposure to a common parasite found in cat feces and contaminated food.

The primary types of drug classes in the toxoplasmosis treatment drugs market include pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and other variations. Chronic toxoplasmosis infection refers to a prolonged infection caused by the protozoan parasite Toxoplasma gondii. Indications for these drugs include both chronic toxoplasmosis infection and acute toxoplasmosis infection. The administration of these drugs can be through parenteral or oral routes and distribution occurs through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The toxoplasmosis treatment drugs market research report is one of a series of new reports from The Business Research Company that provides toxoplasmosis treatment drugs market statistics, including toxoplasmosis treatment drugs industry global market size, regional shares, competitors with a toxoplasmosis treatment drugs market share, detailed toxoplasmosis treatment drugs market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. This toxoplasmosis treatment drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.32 billion in 2024 to $3.52 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to limited treatment options, increased awareness of toxoplasmosis, growing prevalence of toxoplasmosis, expansion of healthcare infrastructure, evolving regulatory landscape

The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to research and development investments, emerging therapies for toxoplasmosis, increasing healthcare expenditure, global initiatives for infectious disease control, adoption of personalized medicine approaches. Major trends in the forecast period include development of combination drug therapies, integration of precision medicine in treatment strategies, emphasis on early diagnosis and intervention, customized treatment regimens, advances in drug delivery methods.

The increasing prevalence of toxoplasmosis infections is anticipated to drive the growth of the toxoplasmosis treatment drug market in the future. Toxoplasmosis refers to the infection and illness caused by the protozoan parasite Toxoplasma gondii in both humans and animals. The rise in toxoplasmosis infections heightens the demand for medications such as pyrimethamine, spiramycin, and leucovorin, which are used to treat patients with specific types of toxoplasmosis, thereby boosting the market for these treatment drugs. For example, in February 2024, data released by the UK Health Security Agency, a government organization in the UK, indicated that 54 confirmed cases of toxoplasmosis were reported in the second quarter of 2023, an increase from 37 cases during the same period in 2022. Consequently, the rising prevalence of toxoplasmosis infections is fueling growth in the toxoplasmosis treatment drug market.

The increasing geriatric population is expected to drive the growth of the toxoplasmosis treatment drug market in the future. Geriatrics focuses on the medical care of older individuals, a demographic that can be challenging to define precisely. Treating the geriatric population for toxoplasmosis requires a comprehensive approach. It is essential to balance efficacy with safety through personalized treatment plans, invest in research for new drugs and therapeutic methods, and emphasize prevention to ensure optimal care for older adults facing this infection. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a U.S.-based agency of the UN Secretariat, projected that the number of individuals aged 65 and older worldwide would more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Thus, the growing geriatric population is driving the expansion of the toxoplasmosis treatment drug market.

Innovation in product offerings emerges as a prominent trend in toxoplasmosis treatment drugs. Leading companies in the market are actively developing advanced products to maintain their market position. An example of this trend is Meitheal Pharmaceuticals, a US-based pharmaceutical company, which, in September 2023, introduced Leucovorin Calcium for Injection in five different forms. These forms include single-dose vials containing 50 mg, 100 mg, 200 mg, 350 mg, and 500 mg. The intended use of leucovorin calcium for injection is in conjunction with high-dose methotrexate therapy for osteosarcoma.

Strategic investments are a key focus for major players in the toxoplasmosis treatment drug market. Such investments are made with a long-term objective, such as gaining a competitive edge, entering new markets, or developing innovative technologies. For instance, ASTRA Therapeutics, a UK-based drug development company, secured funding of CHF 150,000 ($173,787.15) in April 2023. This investment is earmarked for the development of therapies addressing parasite diseases such as malaria, cryptosporidiosis, and toxoplasmosis, which adversely affect millions of people globally and result in significant disease and productivity losses in cattle and agriculture.

In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, engaged in an asset purchase agreement with Phoenixus AG, a Swiss-based biopharmaceutical company. Through this agreement, both companies aim to sell the rights to Daraprim, a prescription drug containing pyrimethamine used for treating toxoplasmosis when combined with a sulfonamide, and Vecamyl, used to treat moderately severe to severe essential hypertension, as well as simple cases of malignant hypertension.

Major companies operating in the toxoplasmosis treatment drugs market include Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca plc, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Ltd., Alvogen Group Inc, Manus Aktteva Biopharma LLP

North America was the largest region in the toxoplasmosis treatment drugs market in 2024. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the toxoplasmosis treatment drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Toxoplasmosis Treatment Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on toxoplasmosis treatment drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for toxoplasmosis treatment drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The toxoplasmosis treatment drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Pyrimethamine; Spiramycin; Leucovorin; Sulfadiazine; Folic Acid; Other Drug Class
• 2) By Indication: Chronic Toxoplasmosis Infection; Acute Toxoplasmosis Infection
• 3) By Route Of Administration: Parenteral; Oral
• 4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Pyrimethamine: Brand Name Variants; Combination Therapies
• 2) By Spiramycin: Brand Name Variants; Formulations
• 3) By Leucovorin: Dosage Forms
• 4) By Sulfadiazine: Brand Name Variants; Combination Therapies
• 5) By Folic Acid: Supplement Formulations; Combination Products With Other Drugs
• 6) By Other Drug Class: Atovaquone; Clindamycin; Trimethoprim-Sulfamethoxazole (TMP-SMX); Experimental Or Emerging Therapies
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Toxoplasmosis Treatment Drugs Market Characteristics

3. Toxoplasmosis Treatment Drugs Market Trends And Strategies

4. Toxoplasmosis Treatment Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Toxoplasmosis Treatment Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Toxoplasmosis Treatment Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Toxoplasmosis Treatment Drugs Market Growth Rate Analysis
• 5.4. Global Toxoplasmosis Treatment Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Toxoplasmosis Treatment Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Toxoplasmosis Treatment Drugs Total Addressable Market (TAM)

6. Toxoplasmosis Treatment Drugs Market Segmentation

• 6.1. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pyrimethamine
• Spiramycin
• Leucovorin
• Sulfadiazine
• Folic Acid
• Other Drug Class
• 6.2. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Toxoplasmosis Infection
• Acute Toxoplasmosis Infection
• 6.3. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• 6.4. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.5. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Pyrimethamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Variants
• Combination Therapies
• 6.6. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Spiramycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Variants
• Formulations
• 6.7. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Leucovorin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dosage Forms
• 6.8. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Sulfadiazine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Variants
• Combination Therapies
• 6.9. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Folic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supplement Formulations
• Combination Products With Other Drugs
• 6.10. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atovaquone
• Clindamycin
• Trimethoprim-Sulfamethoxazole (TMP-SMX)
• Experimental Or Emerging Therapies

7. Toxoplasmosis Treatment Drugs Market Regional And Country Analysis

• 7.1. Global Toxoplasmosis Treatment Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Toxoplasmosis Treatment Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Toxoplasmosis Treatment Drugs Market

• 8.1. Asia-Pacific Toxoplasmosis Treatment Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Toxoplasmosis Treatment Drugs Market

• 9.1. China Toxoplasmosis Treatment Drugs Market Overview
• 9.2. China Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Toxoplasmosis Treatment Drugs Market

• 10.1. India Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Toxoplasmosis Treatment Drugs Market

• 11.1. Japan Toxoplasmosis Treatment Drugs Market Overview
• 11.2. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Toxoplasmosis Treatment Drugs Market

• 12.1. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Toxoplasmosis Treatment Drugs Market

• 13.1. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Toxoplasmosis Treatment Drugs Market

• 14.1. South Korea Toxoplasmosis Treatment Drugs Market Overview
• 14.2. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Toxoplasmosis Treatment Drugs Market

• 15.1. Western Europe Toxoplasmosis Treatment Drugs Market Overview
• 15.2. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Toxoplasmosis Treatment Drugs Market

• 16.1. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Toxoplasmosis Treatment Drugs Market

• 17.1. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Toxoplasmosis Treatment Drugs Market

• 18.1. France Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Toxoplasmosis Treatment Drugs Market

• 19.1. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Toxoplasmosis Treatment Drugs Market

• 20.1. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Toxoplasmosis Treatment Drugs Market

• 21.1. Eastern Europe Toxoplasmosis Treatment Drugs Market Overview
• 21.2. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Toxoplasmosis Treatment Drugs Market

• 22.1. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Toxoplasmosis Treatment Drugs Market

• 23.1. North America Toxoplasmosis Treatment Drugs Market Overview
• 23.2. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Toxoplasmosis Treatment Drugs Market

• 24.1. USA Toxoplasmosis Treatment Drugs Market Overview
• 24.2. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Toxoplasmosis Treatment Drugs Market

• 25.1. Canada Toxoplasmosis Treatment Drugs Market Overview
• 25.2. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Toxoplasmosis Treatment Drugs Market

• 26.1. South America Toxoplasmosis Treatment Drugs Market Overview
• 26.2. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Toxoplasmosis Treatment Drugs Market

• 27.1. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Toxoplasmosis Treatment Drugs Market

• 28.1. Middle East Toxoplasmosis Treatment Drugs Market Overview
• 28.2. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Toxoplasmosis Treatment Drugs Market

• 29.1. Africa Toxoplasmosis Treatment Drugs Market Overview
• 29.2. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Toxoplasmosis Treatment Drugs Market Competitive Landscape And Company Profiles

• 30.1. Toxoplasmosis Treatment Drugs Market Competitive Landscape
• 30.2. Toxoplasmosis Treatment Drugs Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Toxoplasmosis Treatment Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Otsuka Pharmaceutical Co. Ltd.
• 31.9. Baxter International Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. AstraZeneca plc
• 31.13. Astellas Pharma Inc.
• 31.14. Daiichi Sankyo Company Limited
• 31.15. Eisai Co. Ltd.

32. Global Toxoplasmosis Treatment Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Toxoplasmosis Treatment Drugs Market

34. Recent Developments In The Toxoplasmosis Treatment Drugs Market

35. Toxoplasmosis Treatment Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Toxoplasmosis Treatment Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Toxoplasmosis Treatment Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Toxoplasmosis Treatment Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer